Sign in

    Rudy Li

    Vice President and Senior Equity Research Analyst at Chardan Capital Markets

    Rudy Li, PhD, CFA is a Vice President and Senior Equity Research Analyst at Chardan Capital Markets specializing in biotechnology with a focus on CNS-related companies. He actively covers firms such as Prothena Corporation, Mind Medicine (MindMed), Centessa Pharmaceuticals, Praxis Precision Medicines, Xenon Pharmaceuticals, and Stoke Therapeutics, demonstrating a notable stock analysis success rate of approximately 79% and an average analyst return of over 20%. With more than six years of experience, Li began his career at Leerink Partners before joining Chardan and holds a PhD in Chemistry from Stony Brook University plus a BS from Jilin University. He is a Chartered Financial Analyst and maintains relevant professional registrations tied to research analyst roles within the financial sector.

    Rudy Li's questions to Stoke Therapeutics (STOK) leadership

    Rudy Li's questions to Stoke Therapeutics (STOK) leadership • Q2 2025

    Question

    Rudy Li from Chardan Capital Markets questioned the higher incidence of CSF protein elevations in the OLE study and asked about any specific concerns, especially for the patients classified as having treatment-emergent adverse events.

    Answer

    CMO Barry Ticho clarified that elevated CSF protein is a known class effect for intrathecally administered oligonucleotides and is a laboratory finding without any associated clinical manifestations in the 81 patients dosed. He emphasized that the long-term safety profile over four years remains favorable and does not present a concern for the Phase 3 study.

    Ask Fintool Equity Research AI

    Rudy Li's questions to Praxis Precision Medicines (PRAX) leadership

    Rudy Li's questions to Praxis Precision Medicines (PRAX) leadership • Q2 2025

    Question

    Rudy Li of Chardan Capital Markets asked about the impact of background therapies on pivotal trial enrollment criteria and what additional data would be needed to support vormatrogene's use in combination with other sodium channel blockers.

    Answer

    President & CEO Marcio Souza stated that the RADIANT study enrolled a real-world sample of aggressively treated patients, including over 30% on cenobamate, and demonstrated a best-in-class safety profile despite this. He expressed no concern about combinations and sees no need to change enrollment criteria, other than providing clearer instructions to physicians on reducing background ASM doses to improve tolerability.

    Ask Fintool Equity Research AI

    Rudy Li's questions to Mind Medicine (MindMed) (MNMD) leadership

    Rudy Li's questions to Mind Medicine (MindMed) (MNMD) leadership • Q2 2025

    Question

    Rudy Li from Chardan Capital Markets inquired about the FDA's data requirements beyond the primary endpoint for a GAD NDA filing and asked about the company's broader pipeline expansion strategy, including potential collaborations.

    Answer

    CEO & Board Director Robert Barrow stated that the primary endpoints from the VOYAGE and PANORAMA studies are expected to be the key components for a potential NDA filing. Regarding pipeline expansion, he affirmed the team is working on more than just MM120 and is always focused on opportunities to drive long-term value, suggesting more updates will come as time progresses.

    Ask Fintool Equity Research AI

    Rudy Li's questions to Mind Medicine (MindMed) (MNMD) leadership • Q2 2025

    Question

    Rudy Li of Chardan Capital Markets inquired about the rate-limiting steps for an NDA filing in GAD beyond the primary endpoint data and asked for the company's strategy on expanding its pipeline through potential collaborations.

    Answer

    CEO Robert Barrow clarified that the 12-week primary endpoint data from the two pivotal GAD studies are the key components expected for a potential NDA filing. Regarding the pipeline, he expressed excitement about internal programs beyond MM120 and the team's capabilities, advising investors to 'stay tuned' for future updates on expansion.

    Ask Fintool Equity Research AI

    Rudy Li's questions to Mind Medicine (MindMed) (MNMD) leadership • Q1 2025

    Question

    Rudy Li inquired about MindMed's view on psychedelic market dynamics, referencing Spravato's growth, and asked about commercial planning for the second half of the year, including leveraging Spravato's infrastructure.

    Answer

    CCO Matthew Wiley noted the large unmet need in GAD and MDD, stating that commercial positioning work will be completed in H2 2025. He views Spravato as an interesting surrogate for reimbursement and capacity but sees a distinct opportunity for MM-120. CEO Robert Barrow added that MM-120's data could support a more expansive opportunity than Spravato.

    Ask Fintool Equity Research AI

    Rudy Li's questions to Mind Medicine (MindMed) (MNMD) leadership • Q4 2024

    Question

    Rudy Li from Chardan asked about the strategic importance of the MDD indication for MM120's competitiveness and when to expect updates on the timing and design of the second MDD study.

    Answer

    CEO Robert Barrow emphasized that pursuing a broad label covering both GAD and MDD is a key strategic differentiator, allowing them to serve a massive patient population and setting them apart from competitors focused on treatment-resistant depression. He did not provide a specific timeline for updates on the second MDD study, stating it will be informed by ongoing progress.

    Ask Fintool Equity Research AI

    Rudy Li's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership

    Rudy Li's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership • Q4 2024

    Question

    Asked about the size of the treated AL amyloidosis patient population, the impact of daratumumab's approval on the market, and the rationale for the PRX012 expansion cohort.

    Answer

    The company quotes a diagnosed and treated population of 16,000 patients in the U.S., which has increased from 15,000 since daratumumab's approval. The PRX012 expansion cohort was an opportunistic way to enroll more patients who were screening for the APOE homozygous 'B' cohorts but were not carriers, allowing for a larger dataset to better characterize the drug.

    Ask Fintool Equity Research AI

    Rudy Li's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership • Q4 2024

    Question

    Rudy Li of Chardan asked about the number of actively treated AL amyloidosis patients, market changes since daratumumab's approval, and the rationale for the 200mg expansion cohort in the PRX012 ASCENT-2 trial.

    Answer

    COO Brandon Smith confirmed the 16,000 U.S. patients cited are diagnosed and actively treated, a number that has increased from ~15,000 since daratumumab's approval. Chief Development Officer Chad Swanson explained the PRX012 expansion cohort was an opportunistic way to enroll more patients who screened for but were not eligible for the APOE homozygous cohorts, allowing for a larger dataset to better characterize the drug's profile.

    Ask Fintool Equity Research AI

    Rudy Li's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership • Q4 2024

    Question

    Rudy Li of Chardan asked about the number of actively treated AL amyloidosis patients, changes in market dynamics since daratumumab's approval, and the rationale for the 200mg expansion cohort in the PRX012 ASCENT-2 trial.

    Answer

    COO Brandon Smith stated that the quoted 16,000 U.S. patients are diagnosed and treated, up from 15,000 since daratumumab's 2021 approval. Chief Development Officer Chad Swanson explained the PRX012 expansion cohort was an opportunistic way to utilize patients who screened for but were not eligible for the rarer APOE homozygous cohorts, thereby building a larger dataset to better characterize the drug.

    Ask Fintool Equity Research AI

    Rudy Li's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership • Q4 2024

    Question

    Rudy Li inquired about the number of AL amyloidosis patients actively treated with standard-of-care and any market dynamic changes since daratumumab's approval. He also asked for the rationale behind the 200mg expansion cohort for PRX012 in the ASCENT-2 trial.

    Answer

    Chief Operating Officer Brandon Smith confirmed their quoted figure of 16,000 U.S. patients are diagnosed and treated, an increase from 15,000 since daratumumab's approval. Chief Development Officer Chad Swanson explained the PRX012 expansion cohort was an opportunistic way to utilize patients screened for the hard-to-enroll APOE homozygous 'B' cohorts, allowing them to build a larger dataset to better characterize the drug.

    Ask Fintool Equity Research AI